Investment firm H.C. Wainwright has revised its price target for Clearside Biomedical (CLSD, Financial), decreasing it from $6 to $5 while maintaining a Buy rating on the stock. This change comes after reviewing the company's first-quarter report. Despite this adjustment, the firm's estimated market value for Clearside remains stable. However, there is an anticipation of an increase in the shares outstanding, according to the firm's analysis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Clearside Biomedical Inc (CLSD, Financial) is $5.57 with a high estimate of $8.00 and a low estimate of $3.00. The average target implies an upside of 547.92% from the current price of $0.86. More detailed estimate data can be found on the Clearside Biomedical Inc (CLSD) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Clearside Biomedical Inc's (CLSD, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Clearside Biomedical Inc (CLSD, Financial) in one year is $0.39, suggesting a downside of 54.65% from the current price of $0.8599. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Clearside Biomedical Inc (CLSD) Summary page.
CLSD Key Business Developments
Release Date: March 27, 2025
- Cash and Cash Equivalents: Approximately $20 million as of December 31, 2024.
- Funding Outlook: Sufficient resources to fund planned operations into the fourth quarter of 2025.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Clearside Biomedical Inc (CLSD, Financial) has successfully completed over 15,000 suprachoroidal injections, showcasing the reliability and safety of their SCS Microinjector.
- Positive results from the ODYSSEY Phase 2b wet AMD clinical trial led to a successful end of Phase 2 meeting with the FDA, aligning on a pivotal Phase 3 program for CLS-AX.
- The company has achieved regulatory milestones in Asia-Pacific regions, with approvals in Australia and Singapore and a new drug application under review in China.
- Clearside Biomedical Inc (CLSD) has multiple partnerships, including with Arctic Vision and REGENXBIO, which are advancing suprachoroidal treatments in various indications.
- The company is exploring additional pipeline opportunities beyond wet AMD, including potential treatments for geographic atrophy using suprachoroidal delivery.
Negative Points
- Clearside Biomedical Inc (CLSD) has cash and cash equivalents totaling approximately $20 million, which may only fund operations into the fourth quarter of 2025, indicating a need for additional funding.
- The company is actively pursuing options to fund the CLS-AX Phase 3 program, including potential partnerships, which suggests financial constraints.
- Enrollment for the Phase 3 trial is expected to take around 12 months, which could delay the timeline for potential market entry.
- The company faces competition in the wet AMD market, which represents over $12 billion in annual sales, from established treatments with proven efficacy.
- There is a risk of variability in clinical trial results due to patient performance on vision tests, which the company is attempting to mitigate through trial design adjustments.
